Related Experiment Video
Updated: Aug 9, 2026

In Vivo Imaging Systems (IVIS) Detection of a Neuro-Invasive Encephalitic Virus
Published on: December 2, 2012
Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision
1CRC Centre for Cancer Research, The Institute of Cancer Research, Sutton, Surrey, UK. rosanne@icr.ac.uk
Abstract:
Fomivirsen (ISIS-2922, Vitravene) is an antisense 21 mer phosphorothioate oligonucleotide with sequence complementarity to the coding region of the major immediate-early gene of human cytomegalovirus (CMV). Developed by Isis Pharmaceuticals Inc, fomivirsen is the first antisense oligonucleotide to receive approval for licensing and is marketed by Novartis' CIBA Vision. Fomivirsen is administered by intravitreal injection to AIDS patients for the treatment of CMV-induced retinitis. In August 1998, the FDA approved the marketing of Vitravene for the local treatment of CMV retinitis [296420], [296780], and both European and Brazilian registration approval followed in the summer of 1999 [335238].
More Related Videos
05:54Transplantation into the Anterior Chamber of the Eye for Longitudinal, Non-invasive In vivo Imaging with Single-cell Resolution in Real-time
Published on: March 10, 2013
06:19In Vivo Imaging of Cx3cr1gfp/gfp Reporter Mice with Spectral-domain Optical Coherence Tomography and Scanning Laser Ophthalmoscopy
Published on: November 11, 2017
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Ophthalmic Drug Delivery Systems
Respiratory Syncytial Virus Disease
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors